Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint ...
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory ...
Valneva granted EC marketing authorization for Ixchiq vaccine
Valneva (VALN) announced that the European Commission has granted marketing authorization in Europe for Valneva’s single-dose vaccine, Ixchiq, ...
Yahoo Finance2d
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
Chikungunya has become an increasingly pressing public health issue, with outbreaks currently ongoing in India, Brazil and the French Island of La Réunion. Valneva announced last week that it has ...
Pharmabiz1d
Valneva submits label extension application for Ixchiq with UK MHRA to expand its use to adolescents aged 12 to 17 years in EU
Saint Herblain, France Tuesday, April 1, 2025, 16:00 Hrs [IST] ...
Pharmabiz6d
Valneva responds to French govt’s call for supply of chikungunya vaccine, Ixchiq
Valneva SE, a specialty vaccine company, announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion with its vaccine Ixchiq. In agreement ...